StockMarketWire.com - Ixico said Monday it signed a new contract with a top 10 pharmaceutical company, an existing client.

The contract value is £1.0m over a three year term.

Under the terms of the agreement, Ixico would provide its technology-enabled imaging services in a natural history study of people with early manifest Huntington's disease to observe the natural progression of the disease.

Ixico would also use its TrialTracker digital platform and its proprietary image analysis algorithms to collect and analyse the collection of MRI scans.

'Today's announcement continues Ixico's successful track record in providing neuroimaging clinical trial services for Huntington's disease, representing our third new contract in this therapeutic area in the current financial year,' said Giulio Cerroni, Chief Executive of Ixico.



At 9:58am: [LON:IXI] IXICO plc share price was 0p at 31.5p



Story provided by StockMarketWire.com